AMGN

NasdaqGS

Amgen Inc.

Healthcare

Drug Manufacturers - General

United States

447.21USD

+2.58 (+0.58%)

Market Cap: 240.38B USD

Revenue and Net Income

Values in USD

Income Statement

Values in USD

Financial item	TTMJun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Total Revenue	38.09B	36.75B	33.42B	28.19B	26.32B
Cost of Revenue	11.61B	12.04B	12.86B	8.45B	6.41B
Gross Profit	26.48B	24.71B	20.57B	19.74B	19.92B
Operating Expense	15.06B	15.63B	13.31B	11.84B	10.35B
Operating Income	11.43B	9.08B	7.26B	7.90B	9.57B
Net Non Operating Interest Income Expense	-2.67B	-2.75B	-3.15B	-2.88B	-1.41B
Other Income Expense	1.53B	2.65B	506.00M	2.83B	-814.00M
Pretax Income	10.29B	8.98B	4.61B	7.86B	7.35B
Tax Provision	1.54B	1.26B	519.00M	1.14B	794.00M
Net Income Common Stockholders	8.74B	7.71B	4.09B	6.72B	6.55B
Diluted NI Available to Com Stockholders	8.74B	7.71B	4.09B	6.72B	6.55B
Basic EPS	16.22	14.33	7.62	12.56	12.18
Diluted EPS	16.10	14.23	7.56	12.49	12.11
Basic Average Shares	539.00M	538.00M	537.00M	535.00M	538.00M
Diluted Average Shares	543.50M	542.00M	541.00M	538.00M	541.00M
Total Operating Income as Reported	11.43B	9.08B	7.26B	7.90B	9.57B
Total Expenses	26.67B	27.67B	26.17B	20.29B	16.76B
Net Income from Continuing & Discontinued Operation	8.74B	7.71B	4.09B	6.72B	6.55B
Normalized Income	8.74B	7.71B	4.09B	6.72B	6.55B
Interest Expense	2.67B	2.75B	3.15B	2.88B	1.41B
Net Interest Income	-2.67B	-2.75B	-3.15B	-2.88B	-1.41B
EBIT	12.96B	11.73B	7.76B	10.73B	8.75B
EBITDA	17.62B	16.90B	13.36B	14.80B	12.17B
Reconciled Cost of Revenue	11.61B	12.04B	12.86B	8.45B	6.41B
Reconciled Depreciation	4.67B	5.17B	5.59B	4.07B	3.42B
Net Income from Continuing Operation Net Minority Interest	8.74B	7.71B	4.09B	6.72B	6.55B
Total Unusual Items Excluding Goodwill	—	—	—	0.00	0.00
Total Unusual Items	—	—	—	0.00	0.00
Normalized EBITDA	17.62B	16.90B	13.36B	14.80B	12.17B
Tax Rate for Calcs	0.15	0.14	0.11	0.14	0.11
Tax Effect of Unusual Items	0.00	0.00	0.00	0.00	0.00

Key Statistics

Valuation

Market Cap (USD)240.38B

Market Cap (Local)240.38B

P/E (TTM)27.49

P/S (TTM)6.31

MC/EBITDA13.64

Volume & Shares

Last Volume2.05M

Avg Vol (10D)2.46M

Avg Vol (30D)3.18M

Avg Vol (90D)2.70M

Shares Outstanding540.63M

Growth Indicators

Revenue TTM/Ann1.04

Net Income TTM/Ann1.13

EBITDA TTM/Ann1.04

Gross Profit TTM/Ann1.07

Operating Inc TTM/Ann1.26

Currency & Exchange

Trading CurrencyUSD

Financial CurrencyUSD

Trading/USD Rate1.00

Financial/USD Rate1.00

ExchangeNasdaqGS

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease Prolia to treat postmenopausal women with osteoporosis XGEVA for skeletal-related events prevention Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization Nplate for the treatment of patients with immune thrombocytopenia KYPROLIS to treat patients with relapsed or refractory multiple myeloma Aranesp to treat a lower-than-normal number of red blood cells and anemia EVENITY for the treatment of osteoporosis in postmenopausal for women Vectibix to treat patients with wild-type RAS metastatic colorectal cancer BLINCYTO for the treatment of patients with acute lymphoblastic leukemia TEPEZZA to treat thyroid eye disease and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE BEONE MEDICINES LTD. to develop and commercialize Aimovig UCB for the development and commercialization of EVENITY Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.